Alnylam pharmaceuticals reports third quarter 2021 financial results and highlights recent period activity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the third quarter ended september 30, 2021 and reviewed recent business highlights. “our third quarter commercial performance was highlighted by strength from onpattro, and continued execution on the on-going launches of givlaari and oxlumo. another notable achievement was our announcement of positive topline 18-month resul
ALNY Ratings Summary
ALNY Quant Ranking